Home Page

- Amend to: Anti-Infectives

About Us



- Amend to: (ASX:RCE, FSE:R9Q)

Recce (pronounced Re-Key) originates from the military term 'Reconnaissance' as a military tactic – 'the aggressive assessment of the disposition of the enemy'. In other words, get troops behind enemy lines, identify the enemy, eliminate the threat, and escape without being noticed.

We have adopted this approach to anti-infectives, where they are designed to:

- Enter the human body;
- Find the infection and threat (deadly bacteria and viruses);
- Eliminate the threat; and
- Exit without being noticed (side effects)

Recce Pharmaceuticals was founded by Dr Graham Melrose, a former Executive Director and head of research at johnson and johnson asia pacific and australia. building upon his early, independent research, Recce Pharmaceuticals was formed.

- Capitalise highlighted text to Head of Research at Johnson and Johnson Asia Pacific and Australia

Our Visions and Values

"To address the global health threat of antimicrobial with a revolutionary portfolio of synthetic infectives."

Discover

New synthetic polymer-based drugs uniquely designed for targeting major human health threats.

Patent

With over 40 granted patents and patent applications across four families, Recce is well positioned to continue expanding its wholly owned international patent

Commercialise

As an Australian Stock Exchange (ASX:RCE) listed company, Recce Pharmaceuticals Ltd is well funded to pursue its drug development activities with a particular focus on

- Amend to: "To address the global health threat of antimicrobial resistance with a revolutionary portfolio of synthetic anti-infectives"

Commercial Strategy

We are committed to addressing the global health threat posed by antibiotic resistant superbugs and emerging viral pathogens through pioneering a New Class of Synthetic Anti-Infectives. Our approach to treating bacterial and viral infections has the potential to transform the current anti-infective business model.

Proprietary **new class of anti-infectives** against bacteria and viruses, protected by Composition of Matter Patent.

- Amend to: antibiotic-resistant



- Lowercase: and

Board of Directors page



- Hyphenate antibiotic-resistant



- Use alan's updated photo (see attached on upwork)
- Amend Alan's bio to: US based, Director of Palatin Technologies. Over three decades of senior pharmaceutical experience incl. President and MD of Janssen Research Foundation (Johnson & Johnson). Dr Dunton has advanced a number of blockbuster antibiotics through regulatory review and commercialization at Fortune 500 companies including J&J and Roche.

Maggie Niewidok

Company Secretary

Maggie is an admitted lawyer and employee of Automic Group. Maggie is an experienced corporate lawyer and is the Company Secretary to various ASX Listed and unlisted companies, across a range of industries.

- Update maggie's bio to this: Maggie is an admitted lawyer and employee of Kardos Scanlan Corporate Lawyers. Maggie is an experienced corporate lawyer and is the Company Secretary to various ASX Listed and unlisted companies, across a range of industries.

Dr Philip Sutton

Vice President of Translational Sciences

BSc (Hons), PhD

Global infectious disease expert with over 30 years of research and industry experience, having served as former Head of Immunology at CSL Ltd in Melbourne. Chief Editor of textbook "Helicobacter pylori in the 21st Century" and has co-authored 92 manuscripts published in peer-reviewed journals.

- Remove Dr Philip Sutton from website

Intellectual Property

Home > Company > Intellectual Property

Recce Pharmaceuticals currently has four wholly owned patent families, which include over 30 patents or patent applications and are constantly expanding, broadening, and developing the intellectual property portfolio.

Recce is committed to protecting its intellectual property estate of patent rights and trade secrets as well as the potential commercial and/or clinical advantages this protection provides for its proprietary technology.

Recce's patent portfolio includes issued patents and patent applications in the world's major markets, including the United States, Europe, Japan, China and Australia.

Patent Families

Patent Family 1 – Granted

Protecting Recce's unique and highly economical manufacturing process.

Filed	Expiry	Status
Australia	2028	Granted

- Update number to 40

Patent Family 3 – Provisional

Protecting Recce's anti-viral and anti-cancer applications.

Filed	Expiry	Status
Australia	2037	Pending
USA	2037	Granted
Europe	2037	Granted
Germany	2037	Granted
Spain	2037	Granted
France	2037	Granted
UK	2037	Granted
Italy	2037	Granted
Sweden	2037	Granted
Japan	2037	Granted

- Change to granted

Science > Pipeline

Asset and Route of administration	Indications
R327 Intravenous*	Serious/life threatening bacterial infections including sepsis
	Urinary tract infections including urosepsis
	Multidose, early stage sepsis efficacy study
R327 Topical*	Wound infections including infected burns
	Diabetic Foot Ulcers
RCE Compounds*	*Mycobacterium abscessus* pre-clinical program
	Bacterial Sinusitis pre-clinical program
	Additional TBA pre-clinical program

- Please match the pipeline wording below (ignore text colours)

Asset and Route of Administration	Indications
R327 Intravenous*	Serious/life threatening bacterial infections including sepsis
	Urinary tract infections including urosepsis
	Multidose, early stage, rapid infusions sepsis efficacy study
R327 Topical*	Wound infections including infected burns
	Diabetic Foot Ulcer Infections
Pre-Clinical Programs* *Various routes of administration*	*Mycobacterium abscessus*
	Bacterial Sinusitis
	Additional TBA

Anti-bacterial program

Mechanism of action page



- Italicise all E. coli and S. aureus words across the website



- If these four videos could be embedded into the page – please use this link to access the 4 video files https://we.tl/t-xsjGkzLjf7



- Add space between "course" and "The Company"

Manufacturing page



- Full-stop missing

Sepsis page



- Remove I from “Solution”

Burn Wound Infection Page



- Italicise staphylococcus aureus (s.aureus)

Events and presentations page



- Please ensure all these links are linked to the correct files – please check all files in all sections.

Top 20 shareholders page



- Please add March & April (can gather files from live/existing website)

In the News page

- Can these headlines also be linked to the full article? - Thanks